HRS-1635

HRS-1635 is a novel Bruton's tyrosine kinase (BTK) degrader being developed by Chengdu Suncadia Medicine, a subsidiary of Jiangsu Hengrui Pharmaceuticals. Utilizing Proteolysis Targeting Chimera (PROTAC) technology, HRS-1635 is designed to recruit an E3 ubiquitin ligase to the BTK protein, facilitating its ubiquitination and subsequent degradation by the 26S proteasome. This mechanism of action is intended to provide a more comprehensive and durable inhibition of B-cell receptor (BCR) signaling compared to traditional occupancy-based covalent or non-covalent BTK inhibitors. Furthermore, HRS-1635 is specifically engineered to overcome common resistance mechanisms, such as the BTK C481S mutation, which often limits the long-term efficacy of first- and second-generation BTK inhibitors. The drug is currently undergoing Phase 1 clinical evaluation for the treatment of various B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas.